Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Department of Oncology have secured funding to characterise an insulin-like growth factor (IGF) signature for early detection and risk reduction of cancer.

Dr Valentine Macaulay and Dr Guillaume Rieunier have been awarded a 3-year CRUK Early Detection project grant (~£400k) to investigate the role of circulating insulin-like growth factor-1 (IGF-1) in cancer promotion and progression. High levels of circulating IGF-1 have been found to associate with increased risk of developing cancer. This association has been shown for several types of common cancer including cancers of the prostate, breast and colon.

The project will use cell line and in vivo models and clinical data, and will involve collaborators in the Departments of Oncology, Pathology, Surgery and Epidemiology. The research will aim to characterise mediators of high IGF-1 on cancer risk, to provide novel targets for screening and strategies for risk reduction. 

Similar stories

Festive Science Image Competition Winners

Winners of the Medical Research Foundation's second Festive Science Image Competition, run in partnership with the Medical Research Council (MRC), have been announced today.

Robert Watson Awarded ACP McElwain and Presidents Prize

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.

Prof Anna Schuh launches first private specialised haematology clinic and laboratory in sub-Saharan Africa.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.